1. Paradoxical SERCA dysregulation contributes to atrial fibrillation in a model of diet-induced obesity.
- Author
-
Ponce-Balbuena D, Tyrrell DJ, Cruz-Cortés C, Guerrero-Serna G, Da Rocha AM, Herron TJ, Song J, Raza DS, Anumonwo J, Goldstein DR, and Espinoza-Fonseca LM
- Abstract
Obesity is a major risk factor for atrial fibrillation (AF) the most common serious cardiac arrhythmia, but the molecular mechanisms underlying diet-induced AF remain unclear. In this study, we subjected mice to a chronic high-fat diet and acute sympathetic activation ('two-hit' model) to study the mechanisms by which diet-induced obesity promotes AF. Surface electrocardiography revealed that diet-induced obesity and sympathetic activation synergize during intracardiac tachypacing to induce AF. At the cellular level, diet-induced obesity and acute adrenergic stimulation facilitate the formation of delayed afterdepolarizations in atrial myocytes, implicating altered Ca
2+ dynamics as the underlying cause of AF. We found that diet-induced obesity does not alter the expression of major Ca2+ -handling proteins in atria, including the sarcoplasmic reticulum Ca2+ -ATPase (SERCA), a major component of beat-to-beat Ca2+ cycling in the heart. Paradoxically, obesity reduces phospholamban phosphorylation, suggesting decreased SERCA activity, yet atrial myocytes from obese mice showed a significantly increased Ca2+ transient amplitude and SERCA-mediated Ca2+ uptake. Adrenergic stimulation further increases the Ca2+ transient amplitude but does not affect Ca2+ reuptake in atrial myocytes from obese mice. Transcriptomics analysis showed that a high-fat diet prompts upregulation of neuronatin, a protein that has been implicated in obesity and is known to stimulate SERCA activity. We propose a mechanism in which obesity primes SERCA for paradoxical activation, and adrenergic stimulation facilitates AF conversion through a Ca2+ -induced Ca2+ release gain in atrial myocytes. Overall, this study links obesity, altered Ca2+ signaling, and AF, and targeting this mechanism may prove effective for treating obesity-induced AF., Competing Interests: Competing Interest Statement: D.P.-B., D.J.T., C.C.-C., G.G.S., A.M.D.R., J.S., D.S.R., J.A., D.R.G., and L.M.E.-F. declare no competing interests. T.J.H is co-founder of Cartox, Inc., and scientific advisor to StemBioSys, Inc.- Published
- 2024
- Full Text
- View/download PDF